“…Various approaches have been developed recently in order to improve vaccine potency, particularly with the respect to choose of a better adjuvant. To date, despite various adjuvants, such as lipopolysaccharide (LPS) and Freund's complete adjuvant (FCA), have been identified and extensively studied, they are not widely applied due to their toxicity (Abel et al, 2009;Pohanka, Vobornikova, & Fusek, 2016). Hence, only partial adjuvants, such as alum, are licensed for clinical use (Mbow, Gregorio, Valiante, & Rappuoli, 2010).…”